Osteomyelitis Clinical Trial
Official title:
Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses.
The incidence of bone and joint infections (BJI) in children (osteomyelitis, septic arthritis and spondylodiscitis) is 22 per 100,000 children in France. Every year, 3,000 children are hospitalized for BJI, 46% of whom are hospitalized for osteomyelitis. The clinical pictures of BJI are varied: some are severe from the outset; others are non-severe, such as BJIs in Kingella kingae, which are most common in children between the ages of 6 months and 5 years. Currently, the management of children's BJI, regardless of their severity, involves initial hospitalization to start intravenous antibiotic therapy. This non-inferiority trial evaluates, in children with acute osteomyelitis with no severity criteria, less invasive outpatient management with an oral antibiotic treatment given at the outset compared to standard management. Main objective : Demonstrate the non-inferiority of an ambulatory management strategy versus a standard strategy involving hospitalization on complete recovery without relapse at 6 months after an episode of acute osteomyelitis in children aged 1-4 years without severity criteria. Primary endpoint: Complete cure without relapse at 6 months defined by the absence of clinical signs of osteomyelitis at 6 months AND the absence of secondary septic complications (septic arthritis, periosteal abscess) before the end of antibiotic therapy AND the absence of relapse or rehospitalization for osteomyelitis related to the initial infection. This criterion will be assessed blindly by an adjudication committee. Randomized controlled trial of non inferiority, with active control, in open multi-center. The control or experimental arm allocation (1:1 ratio) will be open-label of the physician, patient and parents. This is a PROBE study: The evaluation of the main judgment criterion will be carried out blindly by an adjudication committee.
The incidence of bone and joint infections (BJI) in children (osteomyelitis, septic arthritis and spondylodiscitis) is 22 per 100,000 children in France. Every year, 3,000 children are hospitalized for BJI, 46% of whom are hospitalized for osteomyelitis. The clinical pictures of BJI are varied: some are severe from the outset; others are non-severe, such as BJIs in Kingella kingae, which are most common in children between the ages of 6 months and 5 years. Currently, the management of children's BJI, regardless of their severity, involves initial hospitalization to start intravenous antibiotic therapy. This non-inferiority trial evaluates, in children with acute osteomyelitis with no severity criteria, less invasive outpatient management with an oral antibiotic treatment given at the outset compared to standard management. Main objective : Demonstrate the non-inferiority of an ambulatory management strategy versus a standard strategy involving hospitalization on complete recovery without relapse at 6 months after an episode of acute osteomyelitis in children aged 1-4 years without severity criteria. Primary endpoint: Complete cure without relapse at 6 months defined by the absence of clinical signs of osteomyelitis at 6 months AND the absence of secondary septic complications (septic arthritis, periosteal abscess) before the end of antibiotic therapy AND the absence of relapse or rehospitalization for osteomyelitis related to the initial infection. This criterion will be assessed blindly by an adjudication committee. Randomized controlled trial of non inferiority, with active control, in open multi-center. The control or experimental arm allocation (1:1 ratio) will be open-label of the physician, patient and parents. This is a PROBE study: The evaluation of the main judgment criterion will be carried out blindly by an adjudication committee. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Completed |
NCT03846804 -
Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
|
N/A | |
Active, not recruiting |
NCT04945434 -
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis
|
N/A | |
Recruiting |
NCT06084754 -
Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis
|
N/A | |
Recruiting |
NCT05177107 -
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT02128256 -
CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis
|
Phase 4 | |
Terminated |
NCT01612962 -
Diagnostic Tests to Help Determine Osteomyelitis
|
N/A | |
Terminated |
NCT03091439 -
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT04936958 -
RETR(Osteomyelitis)
|
||
Completed |
NCT03802552 -
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
|
Phase 1 | |
Completed |
NCT03559530 -
Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
|
||
Completed |
NCT00324922 -
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
|
Phase 3 | |
Completed |
NCT02084147 -
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
|
N/A | |
Terminated |
NCT02099240 -
Patients Response to Early Switch To Oral:Osteomyelitis Study
|
Early Phase 1 | |
Withdrawn |
NCT02344511 -
Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis
|
Phase 3 | |
Completed |
NCT00402064 -
The Influence of Bisphosphonates in the Oral Cavity in Children
|
N/A | |
Terminated |
NCT02168816 -
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis
|
Phase 2 | |
Completed |
NCT02685033 -
Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
|
Phase 2 | |
Completed |
NCT02335905 -
Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
|
Phase 1/Phase 2 |